688338.SH
赛科希德
SSE · Healthcare · Medical - Devices · CN
CNY 30.66
−2.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 254.9M | 263.2M | 305.9M | 275.5M | 228.8M |
| Cost of Revenue | 96.5M | 100.8M | 118.1M | 104.7M | 86.2M |
| Gross Profit | 158.4M | 162.4M | 187.8M | 170.8M | 142.6M |
| Operating Expenses | |||||
| R&D Expense | 19.1M | 19.3M | 19.6M | 19.2M | 16.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 20.3M | 20.2M | 25.8M | 13.5M | 12.9M |
| Selling & Marketing Expense | 33.8M | 35.3M | 37.3M | 35.0M | 29.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 68.3M | 66.8M | 62.2M | 38.6M | 27.1M |
| Cost and Expenses | 164.8M | 167.6M | 180.2M | 143.2M | 113.3M |
| Operating Income (EBIT) | 99.3M | 103.6M | 130.0M | 134.9M | 117.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 98.9M | 103.1M | 129.8M | 134.9M | 119.9M |
| Income Tax Expense | 13.2M | 13.6M | 16.9M | 18.0M | 15.8M |
| Bottom Line | |||||
| Net Income | 85.8M | 89.6M | 113.0M | 116.9M | 104.1M |
| Earnings from Cont. Ops | 85.7M | 89.5M | 112.9M | 116.9M | 104.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 85.8M | 89.6M | 113.0M | 116.9M | 104.1M |
| Per Share | |||||
| Basic EPS | CN¥0.82 | CN¥0.85 | CN¥1.07 | CN¥1.10 | CN¥0.98 |
| Diluted EPS | CN¥0.82 | CN¥0.85 | CN¥1.07 | CN¥1.10 | CN¥0.98 |
| Revenue Per Share | CN¥2.51 | CN¥2.50 | CN¥2.90 | CN¥2.59 | CN¥2.15 |
| Shares | |||||
| Basic Shares Outstanding | 101.7M | 105.4M | 105.6M | 106.3M | 106.2M |
| Diluted Shares Outstanding | 101.7M | 105.4M | 105.6M | 106.3M | 106.2M |
| Profitability Metrics | |||||
| EBITDA | — | 116.1M | 141.7M | 138.4M | 121.6M |
| D&A | — | 12.5M | 11.8M | 3.5M | 3.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026